These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26802025)

  • 1. Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.
    Pandey V; Oyer JL; Igarashi RY; Gitto SB; Copik AJ; Altomare DA
    Oncotarget; 2016 Feb; 7(6):7318-28. PubMed ID: 26802025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
    Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
    Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.
    Geller MA; Knorr DA; Hermanson DA; Pribyl L; Bendzick L; McCullar V; Miller JS; Kaufman DS
    Cytotherapy; 2013 Oct; 15(10):1297-306. PubMed ID: 23993303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
    Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
    Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
    Felices M; Chu S; Kodal B; Bendzick L; Ryan C; Lenvik AJ; Boylan KLM; Wong HC; Skubitz APN; Miller JS; Geller MA
    Gynecol Oncol; 2017 Jun; 145(3):453-461. PubMed ID: 28236454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo expansion of CD56+ NK and NKT-like lymphocytes from peripheral blood mononuclear cells of patients with ovarian neoplasia.
    Alves PCM; De Angelo Andrade LAL; Petta CA; Lorand-Metze I; Derchain SF; Guimarães F
    Scand J Immunol; 2011 Sep; 74(3):244-252. PubMed ID: 21595734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
    Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
    Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded CD56
    Poznanski SM; Nham T; Chew MV; Lee AJ; Hammill JA; Fan IY; Butcher M; Bramson JL; Lee DA; Hirte HW; Ashkar AA
    Cancer Immunol Res; 2018 Oct; 6(10):1174-1185. PubMed ID: 30018043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.
    Cheng M; Ma J; Chen Y; Zhang J; Zhao W; Zhang J; Wei H; Ling B; Sun R; Tian Z
    Cell Transplant; 2011; 20(11-12):1731-46. PubMed ID: 21669033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer.
    Hermanson DL; Bendzick L; Kaufman DS
    Methods Mol Biol; 2016; 1441():277-84. PubMed ID: 27177674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome.
    Cifaldi L; Prencipe G; Caiello I; Bracaglia C; Locatelli F; De Benedetti F; Strippoli R
    Arthritis Rheumatol; 2015 Nov; 67(11):3037-46. PubMed ID: 26251193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation of functional human natural killer cells with anti-HIV-1 activity in NOD/SCID/Jak3(null) mice.
    Hattori S; Matsuda K; Kariya R; Harada H; Okada S
    Microbiol Immunol; 2016 Feb; 60(2):106-13. PubMed ID: 26708420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer.
    Samara P; Skopeliti M; Tsiatas ML; Georgaki S; Gouloumis C; Voelter W; Dimopoulos AM; Bamias A; Tsitsilonis OE
    Anticancer Res; 2016 Jul; 36(7):3373-82. PubMed ID: 27354596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the cytotoxic response against ovarian cancer by immune effector cells isolated and expanded from normal donors and ovarian cancer patients.
    Ingersoll SB; Stoltzfus GP; Merchant MH; Ahmad S; Edwards CR; Ahmed A; Oyer JL; Finkler NJ; Holloway RW; Edwards JR
    Cytotherapy; 2012 Jul; 14(6):716-23. PubMed ID: 22409787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody.
    Lee HR; Son CH; Koh EK; Bae JH; Kang CD; Yang K; Park YS
    Sci Rep; 2017 Sep; 7(1):11075. PubMed ID: 28894091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model.
    Lee JM; Yoon SH; Kim HS; Kim SY; Sohn HJ; Oh ST; Oh IH; Kim TG
    Cancer Gene Ther; 2010 Oct; 17(10):742-50. PubMed ID: 20559334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.
    Quintarelli C; Sivori S; Caruso S; Carlomagno S; Falco M; Boffa I; Orlando D; Guercio M; Abbaszadeh Z; Sinibaldi M; Di Cecca S; Camera A; Cembrola B; Pitisci A; Andreani M; Vinti L; Gattari S; Del Bufalo F; Algeri M; Li Pira G; Moseley A; De Angelis B; Moretta L; Locatelli F
    Leukemia; 2020 Apr; 34(4):1102-1115. PubMed ID: 31745215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
    Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
    Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
    Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
    Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.